Article

Certain Criteria Beat DSM-IV in Identifying Bipolar Disorder in Major Depression

Using bipolarity-specifier criteria on patients suffering from major depressive episodes is a valid method of identifying bipolar disorders.

According to a recent study, using bipolarity-specifier criteria on patients suffering from major depressive episodes (MDE) is a valid method of identifying bipolar disorders; the study also found that it identifies more cases than using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.

Jules Angst, MD, from the Zürich University Psychiatric Hospital in Switzerland, and fellow researchers focused on the frequency of the bipolar disorder symptoms in 5,635 patients who suffered for MDE symptoms.

The researchers utilized both DSM-IV-TR criteria and bipolarity-specifier criteria in order to assess the frequency of bipolar disorder; other factors connected to bipolarity were assessed by logistic regression.

Of the 5,635 participants, the investigators discovered that 903 patients (16%) met the DSM-IV-TR criteria of bipolar disorder, while 2,647 patients (47%) met the bipolarity-specifier criteria.

When the researchers applied both definitions, family history of mania or hypomania and multiple past mood episodes were associated considerably with bipolarity (odds ratio, >2).

Further, the researchers reported that the bipolarity-specifier criteria identified connections between comorbid substance-use disorder and manic/hypomanic states throughout antidepressant therapy, as well as current mixed mood symptoms.

"These results suggest that bipolar features are more frequent in patients with MDE than indicated by DSM-IV-TR criteria," the authors wrote.

This study was published in the August issue of the Archives of General Psychiatry.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.